Precision radiation for solid tumors that have run out of options.
STnRadio is developing a first-in-class anti-STn radio-theranostic platform that combines a highly selective antibody with modern targeted radiation, targeting all solid tumors that express STn. We bring precision radiation to cancers that have run out of options.
A highly selective binder
Our platform is built on an antibody that binds Sialyl-Tn (STn), a glycan expressed on most solid tumors and largely absent from healthy tissue. In published comparisons, the antibody shows superior selectivity to historical anti-TAG72 benchmarks.
A modern theranostic approach
A diagnostic imaging step identifies patients whose tumors take up the agent, before any therapeutic dose is given. The therapy is then delivered with bioorthogonal precision — only where it is needed.
Focused on real unmet need
Our platform targets all solid cancers that express Sialyl-Tn (STn), a glycan found on most carcinomas and largely absent from healthy tissue. We are focused on bringing meaningful benefit to patients whose tumors are refractory to conventional treatment.
“Many cancers are not killed by the drugs we have. They are out of reach, or they live in compartments where chemotherapy cannot follow. We are building a way to reach them — and a way to know when we have.”
Building a new generation of targeted radiation therapy.
If you are an investor, a clinician, a scientist or a potential partner, we'd like to hear from you.